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Background: Transcatheter aortic valve implantation (TAVI) is an alternative to surgical aortic valve replacement
(SAVR) in patients with aortic stenosis (AS) and high surgical risk. Hemodynamic performance after TAVI is superior,
but the impact of reverse remodeling on clinical improvement is controversial. We aim to address the differences in
hemodynamic changes between SAVR and TAVI, and its correlation with LV remodeling and clinical improvement
at 6 months follow-up.
Methods: Forty-two patients treated by TAVI were compared with 45 SAVR patients with a stented bioprosthesis.
Clinical, 2D and 3D echocardiographic data were prospectively obtained before and six months after intervention.
Results: Patients had similar distribution for sex, body surface area and AS severity. TAVI patients were older, more
symptomatic and had more comorbidities. They also had higher LV filling pressures, larger 3D indexed left atrium
volume, but similar 3D indexed LV mass. At 6 months, TAVI patients had greater clinical improvement and higher
effective orifice area index (EAOI), but only SAVR patients already had a significant decrease in 3D indexed LV mass
and diastolic volume. In univariate analysis older age, NYHA class ≥ III, increase in EAOI and TAVI were related with
functional class improvement. After multivariate analysis only NYHA class ≥ III (OR 8.81, CI:2.13-36.52; p = 0.003) and
an increase in EAOI ≥ 105% (OR 3.87, CI:1.02-14.70; p = 0.04) were predictors of clinical improvement.
Conclusions: At 6 months, functional class improvement was greater after TAVI. Higher initial NYHA class and an
increase in EAOI ≥ 105% were independently associated with functional enhancement. It is debatable if left
ventricular remodeling is determinant for functional class improvement.
Keywords: Aortic stenosis, Transcatheter aortic valve replacement, Surgical aortic valve replacement, Left ventricular
mass, Reverse remodeling, Clinical improvementBackground
Aortic stenosis (AS) is the most prevalent of all valvular
diseases in developed countries and its increase has a
direct relation with population aging [1]. In elderly pa-
tients cardiac surgery can be challenging by the increased
number of comorbidities, making transcatheter aortic
valve implantation (TAVI) an atractive alternative treat-
ment modality [2].* Correspondence: cristina.gavina@gmail.com
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unless otherwise stated.Surgical aortic valve replacement (SAVR) nearly nor-
malizes long-term survival and improves quality of life
in AS patients [3,4] but late outcomes depend mainly on
the stage of heart disease before surgery, prosthetic re-
lated complications, and comorbidities. Although there
is a significant reduction of wall stress and left ventricu-
lar (LV) pressure after SAVR, nearly half of patients have
residual LV hypertrophy (LVH) late after surgery [5,6].
This persistent increase in LV mass is an independent
predictor of cardiac-related morbidity [6] and mortality
[7] making reverse remodeling an important outcome
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inferior to SAVR in high-risk patients [2] and superior
to medical therapy [8]. TAVI patients have higher effect-
ive orifice areas (EOA) and lower transprosthetic gradi-
ents but, in spite of remarkable clinical improvement,
LV mass regression and reverse remodeling are less con-
sistent in comparison with SAVR [9-11].
In this study we aim to address the differences in
hemodynamic changes between SAVR and TAVI pa-
tients, and its correlation with LV remodeling and clin-
ical improvement at 6 months follow-up.
Methods
Patient selection and follow-up
The present study is a comparison of two prospective
cohorts of patients with symptomatic degenerative se-
vere AS (defined as aortic valve area ≤1 cm2) and LV
ejection fraction (EF) ≥ 40%, who underwent SAVR with
a stented bioprosthesis or TAVI. This was a collabora-
tive work from two distinct institutions since one of
them didn’t have a TAVI program at the time of pa-
tient inclusion.
Patients with aortic regurgitation > II/IV, moderate to
severe mitral or tricuspid regurgitation, significant cor-
onary artery disease (lesions >50% on coronary angiog-
raphy) or previous cardiac surgery were excluded. All
patients had a clinical and echocardiographic evaluation
before and at 6 months after the procedure, if alive.
This investigation conforms to the Declaration of
Helsinki, had institutional ethical review board approval
and each study participant signed an informed consent
before enrolment.
TAVI group
Forty-two consecutive patients with severe aortic sten-
osis and preserved LV systolic function, submitted to
successful TAVI in one tertiary center, Hospital Clinico
San Carlos, from April 2009 to April 2010, were inclu-
ded. These patients were obtained from a series of 97
consecutive patients who underwent TAVI, after exclud-
ing those with significant LV systolic dysfunction, con-
comitant moderate to severe mitral valve disease or
aortic regurgitation, and those with significant coronary
artery disease.
Patients were referred for TAVI due to an excessive
risk for SAVR, which was estimated using the logistic
EuroSCORE and/or clinical judgment.
Vascular access was obtained either by percutaneous
approach through the common femoral artery (30 pa-
tients) or transapical approach (12 patients).
The procedure was performed under fluoroscopy and
transesophageal echocardiography (TEE) guidance using
the techniques described in detail in previous reports
[12]. Among all, 31 (73.8%) patients were implanted withan Edwards SAPIEN (Edwards Lifesciences, Irvine, CA,
USA). The CoreValve (Medtronic CoreValve Percutaneous
System, Medtronic CV) was implanted in 11 (26.2%) pa-
tients exclusively by retrograde transfemoral approach.
Two valve sizes were available, 23- and 26-mm expanded
diameter for Edwards SAPIEN valve and 26- and 29-mm
for CoreValve. The prosthesis size was decided according
to annulus diameter, measured by TEE. The deployment
was performed under the agreement of the interventionist
and the echocardiographer. Device success was defined as
stable device placement and function as assessed by angi-
ography and echocardiography. All patients with develop-
ing new grade III atrioventricular block were implanted
with a permanent pacemaker within 3 days after valve
implantation.
SAVR group
Between January 2009 and December 2009, among 141
consecutive patients with isolated symptomatic AS referred
for SAVR at the Cardiothoracic Surgery Department of
Centro Hospitalar São João, Porto, Portugal we included
45 patients with 3D echocardiographic evaluation. All sur-
geries were performed using standard procedure for aortic
valve replacement. Patients were placed on cardiopulmo-
nary bypass and cardiac arrest was induced and maintained
with cold blood cardioplegia. The prosthetic substitutes
used in this study were Carpentier-Edwards Perimount
pericardial valve (Edwards Lifesciences, Irvine, CA) and
the St Jude Medical Epic porcine valve (St Jude Medical,
Inc, St Paul, Minn). Valve sizes were 19 mm (n = 4;8.9%),
21 mm (n = 25;55.6%), 23 mm (n = 11;24.4%) and 25 mm
(n = 5;11.1%).
Echocardiographic studies
Echocardiographic examination was performed by a
trained cardiologist and recorded on digital support. All
recordings were examined by an experienced echocardi-
ographer in an accredited independent echocardiography
laboratory (Hospital Clínico San Carlos in Madrid, Spain),
blinded to patient details. Studies were performed using
Phillips iE-33 equipment with a S5-1 transducer with
M-mode, two dimensional, pulsed, continuous, color-flow
and tissue Doppler capabilities, and an X3-1 transducer
for 3D imaging. Imaging analysis was performed with
Xcelera and QLab software. All measurements were per-
formed in accordance with the recommendations of the
American Society of Echocardiography [13]. Peak trans-
valvular gradient was estimated using the simplified
Bernoulli equation. Aortic valve area (or effective orifice
area, EOA) was estimated using quantitative Doppler by
the continuity equation. The EOA values were then in-
dexed to body surface area (EAOI). Patient prosthesis mis-
match was considered present if EAOI ≤0.85 cm2/m2 and
severe when EAOI ≤ 0.65 cm2/m2.
Table 1 Baseline clinical characteristics of SAVR vs TAVI
patients
SAVR (n = 45) TAVI (n = 42) p-value
Age (years) [Me (P25-P75)] 73 (68 - 78) 83.5 (79 - 87) <0.001
Female gender [n(%)] 28 (62.2) 26 (61.9) 0.976
BSA (m2) [Me (P25-P75)] 1.76 (1.57 - 1.86) 1.75 (1.6 - 1.8) 0.639
Hypertension [n(%)] 28 (62.2) 35 (83.3) 0.028
Diabetes mellitus [n(%)] 13 (28.9) 11 (26.2) 0.778
Dislipidemia [n(%)] 28 (62.2) 26 (61.9) 0.976
COPD [n(%)] 12 (26.7) 19 (45.2) 0.071
PAD [n(%)] 3 (6.7) 12 (28.6) 0.007
Atrial Fibrilation [n(%)] 0 (0) 7 (16.7) 0.004
Logistic Euroscore 6.18 ± 2.71 17.86 ± 9.55 <0.001
NYHA class III-IV [n(%)] 12 (26.7) 37 (88.1) <0.001
BSA = body surface area; COPD = chronic obstructive pulmonary disease;
PAD = peripheral artery disease; NYHA = New York Heart Association; values
are mean ± SD or median (P25-P75) according to distribution, or n (%).
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valvular) of aortic regurgitation (AR) were classified as
trivial, mild, moderate, or severe according to The Valve
Academic Research Consortium (VARC) II [14].
Mitral inflow was assessed in the apical 4-chamber
view using pulsed wave Doppler with the sample volume
placed at the tips of mitral leaflets during diastole. From
the mitral inflow profile, the peak flow velocity of early
filling (E wave), peak flow velocity of atrial contraction
(A wave), the E/A ratio, and early filling deceleration
time (DT) were measured. Doppler tissue imaging of the
mitral annulus was obtained from the apical 4-chamber
using a sample volume placed in the septal mitral valve
annulus. The septal e’ velocity value was determined,
and the E/e’ ratio was derived.
Left atrium (LA) volume, LV systolic and diastolic vol-
umes, and resulting ejection fraction were calculated
with direct 3D volumetric analysis.
All indexed values were obtained by dividing by body
surface area according to the formula of Mosteler.
Statistical analysis
Categorical variables were expressed as percentages and
continuous variables as mean ± standard deviation or
median and interquartile range, according to their distri-
bution. Continuous variables were compared between
groups using an unpaired t-test (for normally distributed
variables) or the Mann–Whitney U-test (for non-normally
distributed variables). For comparison between base-
line and follow-up a paired Student's t-test was ap-
plied (normally distributed variables) and a Wilcoxon
test (for non-normal distributed variables). Chi-square test
was used to compare proportions. Following univariate
analysis, a stepwise binary logistic multivariate regression
model (Wald backward stepwise method, p = 0.05 for co-
variate inclusion and 0.1 for exclusion) was performed, in-
cluding potential confounders for NYHA improvement
regression analysis 6 months after AVR. NYHA improve-
ment was analyzed as worse or equal vs better. Of note,
patients in baseline NYHA class I but symptomatic
(angina or syncope) were considered improved if these
additional symptoms disappeared.
All reported probability values are two-tailed, and p <
0.05 was considered statistically significant. Analyses were
performed with the IBM®SPSS® Statistics software package
(version 21.0) (SPSS Inc, Chicago, IL, USA).
Results
Patient’s baseline clinical characteristics are described in
Table 1. TAVI patients were older, had more comor-
bidities and higher logistic Euroscore. Patients who un-
derwent TAVI had worse functional class at baseline,
although they had similar baseline severity of aortic
stenosis (Table 2). Before intervention, when comparingto SAVR patients, TAVI patients had similar 3D LV mass
index but, after normalizing LV mass to LV end-diastolic
volume (LVMI/LVDVI), they had more concentric geo-
metry (3.0 (P25-75:2.1-4.4) vs 2.4 (P25-75:1.8-3.0) g/ml;
p = 0.044) due to smaller LV end-diastolic index volumes.
TAVI patients also had worse diastolic dysfunction, with
higher LV filling pressures and larger indexed LA volume
(Table 3).
At 6 months follow-up, 5 TAVI patients had died, 3
during hospitalization for TAVI, and 2 after hospital dis-
charge from non-cardiovascular causes. There were no
deaths in the SAVR group.
Changes in LV remodeling and functional class after
aortic valve replacement
At 6 months (Table 2), TAVI patients had a higher ef-
fective orifice area index (EAOI) and lower transpros-
thetic maximal velocity and mean gradient, as well as a
greater absolute increase in EAOI. Patient-prosthesis mis-
match (PPM) was more frequent in the SAVR patients
and there were no severe PPM cases in the TAVI group.
There was a significant increase in ejection fraction (EF)
in both groups and, when considering LV remodeling
(Table 3), although there was a decrease in LV mass index
(LVMI) and LV diastolic volume index (LVDVI) in both
groups, only in SAVR patients this decrease was signifi-
cant when compared with baseline values (Figure 1).
The presence of patient-prosthesis mismatch had no
correlation with changes in LVMI, LVDVI, LV end-systolic
volume index (LVSVI), or LA volume index (Additional
file 1: Table S1). Moreover, EAOI increase was not re-
lated to final LVMI (r = 0.082, p = 0.512), LVDVI (r = 0.015,
p = 0.925), LVSVI (r = 0.154, p = 0.331), or LAVI (r = 0.187,
p = 0.143).
Table 2 Baseline and 6 months 2D echocardiographic data on SAVR vs TAVI patients
SAVR (n = 45) TAVI (n = 42) SAVR vs TAVI p-value
mean ± SD Me (P25-P75) mean ± SD Me (P25-P75)
AV annulus (cm)
Baseline 21.34 ± 2.18 21 (20 - 22.75) 20.73 ± 2.39 21 (19 - 22) 0.337b
AV peak velocity (cm/sec)
Baseline 4.81 ± 0.60 4.76 (4.36 - 5.13) 4.76 ± 0.61 4.81 (4.36 - 5.16) 0.909b
6 months 2.69 ± 0.74 2.51 (2.21 - 3.00) 2.07 ± 0.51 2.11 (1.72 - 2.31) <0.001a
p-value* <0.001 <0.001
AV mean gradient (mmHg)
Baseline 57.89 ± 13.91 54.9 (47.13 - 66.45) 54.67 ± 15.77 52.5 (44.0 - 60.3) 0.317a
6 months 17.21 ± 12.05 13.9 (11 - 21) 8.86 ± 4.72 8.1 (5.7 - 11.4) <0.001a
p-value** <0.001 <0.001
AVA (EOA, cm2)
Baseline 0.69 ± 0.2 0.7 (0.52 - 0.83) 0.62 ± 0.15 0.6 (0.51 - 0.7) 0.070a
6 months 1.5 ± 0.42 1.4 (1.2 - 1.75) 1.95 ± 0.54 1.8 (1.5 - 2.2) <0.001a
p-value** <0.001 <0.001
AVA index (EAOI cm2/m2)
Baseline 0.40 ± 0.11 0.38 (0.32 - 0.47) 0.37 ± 0.1 0.37 (0.31 - 0.42) 0.229b
6 months 0.87 ± 0.24 0.82 (0.68 - 1.00) 1.16 ± 0.39 1.05 (0.88 - 1.36) <0.001a
p-value* <0.001 <0.001
Δ EAOI (cm2/m2) 0.47 ± 0.28 0.46 (0.3 - 0.59) 0.79 ± 0.37 0.65 (0.55 - 1.03) <0.001a
PPM [n (%)] 24 (58.6) 9 (23.1) <0.001
Severe PPM [n (%)] 7 (17.1) 0 0.012
Paravalvular AR 6m [n (%)] 3 (6.7) 23 (59) <0.001
E/A ratio
Baseline 0.79 ± 0.34 0.72 (0.61 - 0.89) 1.38 ± 0.87 1.07 (0.74 - 1.74) <0.001b
6 months 0.85 ± 0.25 0.81 (0.69 - 0.93) 1.34 ± 1.22 0.73 (0.57 - 1.74) 0.703b
p-value* 0.044 0.212
E-wave deceleration time (ms)
Baseline 235.11 ± 73.97 240 (180 - 280) 207.69 ± 79.97 198 (148 - 238.5) 0.039b
6 months 264.51 ± 72.84 250 (218.5 - 300) 251.82 ± 66.02 260 (190 - 295) 0.755b
p-value* <0.001 <0.001
IVRT (ms)
Baseline 99.09 ± 26.85 100 (80 - 120) 73.4 ± 33.91 70 (50 - 100) 0.001a
6 months 116.43 ± 20.41 110 (100 - 130) 102.19 ± 28.93 100 (82.5 - 127.5) 0.034a
p-value** 0.049 <0.001
e’ (cm/s)
Baseline 4.77 ± 1.8 4.4 (3.6 - 5.8) 5.56 ± 2.55 5 (4.1 - 6.1) 0.157b
6 months 5.59 ± 1.52 5.4 (4.6 - 6.73) 7 ± 3.07 6.1 (4.78 - 8.7) 0.033a
p-value* 0.005 0.495
E/e’
Baseline 18.62 ± 7.11 16.9 (13.27 - 23.68) 23.55 ± 10.88 25.36 (15.99 - 30.78) 0.024b
6 months 16.73 ± 5.96 15.75 (13.02 - 19.86) 16.36 ± 10.77 11.72 (8.33 - 23.06) 0.153b
p-value* 0.096 0.177
AV = aortic valve; AVA = aortic valve area; EAOI = effective orifice area index; Δ EAOI = absolute increase in EAOI; PPM = patient-prosthesis mismatch; IVRT =
Isovolumetric relaxation time; 6m = six months; values are mean ± SD or median (P25-P75) or n (%). a,b – different letters stand for significant differences in mean
or median values according to t-test (a) or the Mann–Whitney U test (b).*Wilcoxon test; **Paired-sample t-test.
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Table 3 Baseline and 6 months 3D echocardiographic data on SAVR vs TAVI patients
SAVR (n = 45) TAVI (n = 42) SAVR vs TAVI p-value*
mean ± SD Me (P25-P75) mean ± SD Me (P25-P75)
LVEDVi (ml/m2)
Baseline 61.77 ± 21.81 59 (43.49 - 75.58) 46.29 ± 13.47 46.59 (34.44 - 55.74) 0.007
6 months 51.28 ± 16.63 47.64 (38.69 - 59.1) 42.07 ± 12.87 38.89 (33.58 - 48.67) 0.030
p-value** 0.001 0.173
LVESVi (ml/m2)
Baseline 27.32 ± 14.68 21.7 (16.56 - 34.86) 20.91 ± 9.81 18.54 (13.98 - 28.44) 0.115
6 months 21.17 ± 11.46 19.54 (13.55 - 24.99) 16.29 ± 7.99 13.56 (10.68 - 23.01) 0.074
p-value** 0.002 0.004
EF (%)
Baseline 57.63 ± 9.38 60.1 (54.8 - 63.5) 55.73 ± 10.15 55.45 (49.45 - 59.83) 0.079
6 months 61.28 ± 8.98 61.7 (58.55 - 66.95) 61.27 ± 11.35 61 (53.5 - 70.2) 0.841
p-value** 0.037 0.005
LVMI (g/m2)
Baseline 135.3 ± 37.5 120.1 (108.4 - 160.2) 137.46 ± 47.76 123.13 (97.5 - 173.89) 0.877
6 months 119.5 ± 36.8 110.7 (96.5 - 128.0) 124.44 ± 44.55 112.53 (98.75 - 155) 0.588
p-value** 0.002 0.537
LVMI/LVDVI
Baseline 2.49 ± 0.81 2.35 (1.84 - 2.96) 3.48 ± 1.7 3 (2.05 - 4.4) 0.038
6 months 2.46 ± 0.68 2.56 (1.9 - 2.92) 3.01 ± 1.53 2.82 (1.81 - 3.65) 0.334
p-value** 0.557 0.424
LAVI (ml/m2)
Baseline 39.94 ± 14.27 37.27 (31.15 - 47.99) 48.42 ± 14.81 47.5 (35.36 - 57.14) 0.008
6 months 38.16 ± 11.9 36.17 (30.19 - 45.24) 40.99 ± 12.7 42.63 (29.44 - 50) 0.425
p-value** 0.465 0.006
LVDVI = left ventricular end-diastolic volume index; LVSVI = left ventricular end-systolic volume index; EF = ejection fraction; LVMI = left ventricular mass index;
LAVI = left atrial volume index; *Mann–Whitney test; **Wilcoxon test.
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TAVI patients compared with 22 (48.8%) SAVR patients
(p = 0.001, Figure 2). Patients exhibiting a better NYHA
class were more likely to have no PPM (81.6% vs 60.0%,
p = 0.049) and a greater relative increase in EAOI (163.2%
(P25-75: 118.9-234.8) vs 103.0% (P25-75: 52.1-170.2);
p = 0.030). In univariate analysis, older age, baseline NYHA
class ≥ III, a higher increase in EAOI and TAVI procedure
were related with functional class improvement (Table 4).
Moreover, we found no correlation between functional
class improvement and parameters of LV reverse remodel-
ing like the decrease in LV volumes or mass, or improve-
ment in diastolic function suggested by the decrease in
left atrial volume and E/e’ (Table 4). After a stepwise lo-
gistic multivariate regression analysis, the only independ-
ent predictors of NYHA class improvement were initial
NYHA class ≥ III (OR 8.81, CI: 2.13-36.52; p = 0.003) and
relative increase in EAOI ≥ 105% (OR 3.87, CI: 1.02-14.70;
p = 0.04).Paravalvular regurgitation was more frequent after TAVI
(59% vs 6.7%, p < 0.001), mostly of mild degree. Only 5
TAVI patients (5.8%) had moderate aortic regurgitation at
six months. Paravalvular regurgitation had no correla-
tion with the variation of indexed LVM, LVDV or LVSV
(Additional file 2: Table S2). NYHA class improvement
was similar in patients with and without paravalvular re-
gurgitation (83.3% vs 66.7%, p = 0.241).
Discussion
In this study we found that, at 6 months, TAVI patients
had a better hemodynamic result and greater clinical im-
provement than those submitted to SAVR, but LV re-
verse remodeling was of a less significant degree than in
SAVR patients.
Reverse remodeling after aortic valve replacement
At 6 months follow-up, TAVI patients had a more favor-
able hemodynamic performance but the decrease in LVMI
Figure 1 Six months changes in parameters of remodeling in TAVI and SAVR groups. A- change in left ventricular mass index (LVMI);
B- change in ratio LVMI/left ventricular end-diastolic volume index (LVDVI); C- change in ejection fraction (EF); D- change in left atrial volume
index (LAVI); E- change in LVDVI; F- change in left ventricular end-systolic volume index (LVSVI).
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SAVR patients, was less extensive.
A greater decrease in transvalvular gradients and in-
crease in effective orifice area was seen after TAVI. It
would be expected that patients undergoing this proce-
dure had faster remodeling if load was the most impor-
tant determinant of mass regression, but in our studyFigure 2 Six months changes in NYHA class in TAVI and SAVR groupsEAOI increase was not associated with changes in LV
mass and volumes after AVR. We can speculate that the
baseline differences we have found, with older age and
more comorbidities in TAVI patients, could have contrib-
uted to this result. Moreover, TAVI patients were “sicker”,
with worse diastolic dysfunction and worse functional
class, despite similar severity of AS and EF, possibly due to.
Table 4 Univariate and multivariate analysis of clinical










Age (years) 1.09 (1.01-1.17) 0.02
ΔEF (%) 0.99 (0.94-1.04) 0.62
ΔLVMI (g/m2) 0.99 (0.97-1.01) 0.49
ΔLAVI (ml/m2) 1.01 (0.99-1.02) 0.38
ΔLVDVI (ml/m2) 0.98 (0.94-1.02) 0.28
ΔLVSVI (ml/m2) 0.99 (0.93-1.05) 0.64
ΔEAOI (%) 8.81 (0.90-86.10) 0.06 3.87 (1.02-14.70) 0.004
ΔE/e’ 1.01 (0.94-1.08) 0.85




COPD [n(%)] 2.55 (0.75-8.66) 0.14
PAD [n(%)] 0.80 (0.22-2.96) 0.74
NYHA class ≥ III
[n(%)]
11.33 (2.93-43.78) <0.001 8.81 (2.13-36.52) 0.003




LVDVI = left ventricular end-diastolic volume index; LVSVI = left ventricular
end-systolic volume index;; LVMI = left ventricular mass index; LAVI = left atrial
volume index; Δ EF = baseline- 6 months ejection fraction; Δ LVDVI = baseline-
6 months LVDVI; Δ LVSVI = baseline- 6 months LVSVI; Δ LVMI = baseline- 6
months LVMI; Δ LAVI = baseline- 6 months LAVI; Δ EAOI = relative increase in
EAOI at 6 months; Δ E/e’ = baseline- 6 months E/e’; COPD = chronic obstructive
pulmonary disease; PAD = peripheral artery disease; TAVI = transcatheter aortic
valve implantation.
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restricted ability of the myocardium to recover from pre-
intervention changes.
Various groups have focused on the hemodynamic and
structural effects of TAVI [10,15-18] with consistent re-
sults in afterload reduction and symptomatic improve-
ment, but with conflicting results on reverse remodeling.
Previous reports comparing the impact of TAVI and
SAVR on LV remodeling addressed heterogeneous popu-
lations, including patients with coronary artery disease,
different levels of EF, and several types of aortic pros-
thesis, including mechanical, stented and stentless bio-
prosthesis [9,11,19].
Clavel et al. [20] compared hemodynamic perfor-
mances of TAVI or SAVR with stentless and stented bio-
prosthesis. At 6 to 12 months the increase in EAOI and
reduction in transvalvular gradients in TAVI patients
was similar to that obtained with stentless bioprosthesis
and there was a clear advantage of TAVI in preventing
PPM in patients with small annulus (≤20 mm). However,data on clinical improvement or reverse remodeling is
absent.
Fairbairn et al. [19], using cardiac magnetic resonance
imaging, showed a decrease in LVMI and indexed LV
systolic volume at 6 months in both groups, but only
SAVR patients had a decrease in indexed LV diastolic
volume. The authors considered that the smaller reduc-
tion in LV end-diastolic volume post-TAVI could be re-
lated to a greater burden of coronary artery disease in
these patients. In our study we found that, at 6 months,
only SAVR patients had a significant decrease in LV
mass and LV end-diastolic volume. Since we excluded
patients with coronary artery disease, the absence of sig-
nificant remodeling post-TAVI at this time point could
indicate the existence of irreversible disease. Constantino
et al. [18] compared reverse remodeling 2 months after
TAVI and SAVR, and concluded that there was a more
significant reduction in LVMI and relative wall thickness
(RWT) in TAVI patients. These results are conflicting
with ours, but were obtained in an earlier time point
and the lack of adjustment for differences in baseline
LVMI could have influenced results. Moreover, the au-
thors found that these structural changes were paralleled
by reduction in estimated filling pressures after TAVI.
We also found a reduction in E/e´ after TAVI, but this
occurred in absence of favorable remodeling and had no
correlation with clinical improvement. Its association
with prognosis is yet to be seen.
In the Cohort A of the PARTNER trial, LV diastolic
volume was higher in TAVI patients in the first year of
follow-up, but these differences were no longer present
at two years. LV mass regression was faster in the SAVR
group, although there were no significant differences
after 6 months [11]. These results are similar to those
reported in our study, suggesting that reverse remodel-
ing can also occur in TAVI patients, but the process is
slower than after SAVR, even after matching for age and
major comorbidities.
Aortic regurgitation after TAVI, mostly paravalvular, is
a common event [2,21] and has come to our attention
because of its impact on mortality. Post-procedural mo-
derate to severe AR increased in-hospital mortality in
comparison with no or only mild AR [21] and, in the
randomized PARTNER trial, there was a positive correl-
ation between AR severity and long-term mortality [22].
The pathophysiology underlying this increase is mortal-
ity is unclear. It has been speculated that significant pa-
ravalvular aortic regurgitation can overload the LV and
impair reverse remodeling [23], therefore worsening prog-
nosis. In our study, the presence of paravalvular aortic re-
gurgitation had no correlation with the variation in LV
volumes or mass. Once only 5 patients had moderate re-
gurgitation, the lack of association with ventricular re-
modeling could be due to the small sample size. Longer
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inite conclusion on its impact in remodeling.
Predictors of clinical improvement
In our sample, the increase in EAOI to more than the
double was a strong predictor for clinical improvement,
independent of changes in parameters of reverse remodel-
ing. Conversely, the presence of patient-prosthesis mis-
match (PPM) was correlated with impaired improvement
in NYHA class.
Several studies reported that PPM is an independ-
ent predictor of cardiac events after AVR [24,25] while
others failed to demonstrate a significant impact on out-
comes [26,27].
Some authors found that persistent PPM results in less
regression [28,29] but even patients with PPM or small
prosthesis can have significant reduction in LVM [30,31].
The extent of regression is largely dependent on the ex-
tent of EOA increase after AVR [32]. Given the curvilinear
relation of indexed EOA and transprosthetic gradients
the degree of regression seems to be dependent on the ori-
ginal and final positions of an individual patient on the
indexed EOA-gradient curve [33]. Although we found no
correlation between PPM and impaired LVMI regression,
we did find that the increase in valve area to more than
twice the initial value was crucial for clinical improve-
ment. This can be particularly important in elderly pa-
tients whose main concern is the achievement of a better
quality of life.
Finally, as expected, patients who were in worse NYHA
class before intervention more frequently experienced a
clinical improvement. Using NYHA class to evaluate clin-
ical improvement, although extensively used, has limita-
tions and it is easier to demonstrate an improvement
when a patient is class III/IV than NYHA class II/I. This
fact can also help to explain the better improvement in
the clinical status of patients undergoing TAVI, as they
were in worse NYHA class than SAVR patients, before the
intervention.
Limitations
Since this was an observational study, we were not able
to match patients for age, comorbidities or prosthesis
size. These factors were considered in the multivariate
model used for prediction of clinical improvement, but
the authors recognize that, although logistic multivariate
analysis is commonly used, it can’t correct for all pos-
sible confounders.
In addition, we selected our population by excluding
patients with concomitant coronary artery disease and
significant associated valvular disease to reduce intro-
duction of further bias. The limited number of patients
included in this analysis has limited statistical power to
detect small differences between groups.The evaluation of functional improvement using NYHA
class is subjective and a more objective method, like six-
minute walk test, could have allowed a quantitative assess-
ment. Nevertheless, in clinical practice, NYHA class is the
most widely use classification of function status and has
been proven useful over the years.
Conclusions
At six months after aortic valve intervention, better
hemodynamic result was seen after TAVI, but LV reverse
remodeling was of a less significant degree than after
SAVR. Older age, comorbidities and the existence of a
more extensive myocardial disease, as suggested by worse
diastolic dysfunction and worse functional class in TAVI
patients, despite similar severity of AS and EF, could ex-
plain a restricted ability of the myocardium to recover
even after load relief. Moreover, six months may be too
early to draw definitive conclusions, namely regarding the
consequences of paravalvular aortic regurgitation.
Mid-term clinical improvement was strongly related to
the increase in EAOI and had no association with LV re-
modeling parameters. Thus, doubling the initial aortic
valve area seems to be a key point to achieve clinical im-
provement after valve replacement, a particularly im-
portant endpoint in the elderly.
This study raises some important new questions but
longer follow-up and large-scale randomized trials are
needed to confirm these results.
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